Literature DB >> 11722797

Frequency of tuberculous and non-tuberculous mycobacteria in HIV infected patients from Bogota, Colombia.

M I Murcia-Aranguren1, J E Gómez-Marin, F S Alvarado, J G Bustillo, E de Mendivelson, B Gómez, C I León, W A Triana, E A Vargas, E Rodríguez.   

Abstract

BACKGROUND: The prevalence of infections by Mycobacterium tuberculosis and non-tuberculous Mycobacterium species in the HIV-infected patient population in Colombia was uncertain despite some pilot studies. We determined the frequency of isolation of Mycobacterium tuberculosis and of non-tuberculous Mycobacterium species in diverse body fluids of HIV-infected patients in Bogota, Colombia.
METHODS: Patients who attended the three major HIV/AIDS health care centres in Bogota were prospectively studied over a six month period. A total of 286 patients were enrolled, 20% of them were hospitalized at some point during the study. Sixty four percent (64%) were classified as stage C, 25% as stage B, and 11% as stage A (CDC staging system, 1993). A total of 1,622 clinical samples (mostly paired samples of blood, sputum, stool, and urine) were processed for acid-fast bacilli (AFB) stain and culture.
RESULTS: Overall 43 of 1,622 cultures (2.6%) were positive for mycobacteria. Twenty-two sputum samples were positive. Four patients were diagnosed with M. tuberculosis (1.4%). All isolates of M. tuberculosis were sensitive to common anti-tuberculous drugs. M. avium was isolated in thirteen patients (4.5%), but only in three of them the cultures originated from blood. The other isolates were obtained from stool, urine or sputum samples. In three cases, direct AFB smears of blood were positive. Two patients presented simultaneously with M. tuberculosis and M. avium.
CONCLUSIONS: Non-tuberculous Mycobacterium infections are frequent in HIV infected patients in Bogota. The diagnostic sensitivity for infection with tuberculous and non-tuberculous mycobacteria can be increased when diverse body fluids are processed from each patient.

Entities:  

Mesh:

Year:  2001        PMID: 11722797      PMCID: PMC60001          DOI: 10.1186/1471-2334-1-21

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Mycobacterium infections are frequent opportunistic pathogens associated with the acquired immunodeficiency syndrome (AIDS). Its relative virulence and potential for person-to-person transmission distinguishes Mycobacterium tuberculosis. Persons infected with the human immunodeficiency virus (HIV) are particularly susceptible to tuberculosis, either by the reactivation of latent infection or by a primary infection with rapid progression to active disease [1-4]. The annual incidence rate of tuberculosis in Colombia during 1998 was 19.6 per 100,000 persons [5], but rates 1,000-fold higher have been reported in some HIV-seropositive populations [6-14]. In addition, disseminated infections with Mycobacterium avium complex are increasingly common in advanced human immunodeficiency virus (HIV) disease and cause substantial morbidity [15,16]. Persons with HIV infection and CD4 lymphocyte counts less than 100 cells/mm3 have a probability of 10% to 20% per year of developing M. avium complex disease or bacteremia [17,18]. Bacteremia involving M. avium complex produces a wide array of clinical signs and symptoms, including wasting, fever, and night sweats, and is associated with decreased survival [17-20]. The recovery of mycobacteria in blood cultures can help to discover bacteremia that frequently goes unrecognized. We undertook a prospective survey in three AIDS health care units in Bogota, Colombia, in order to determine the prevalence of Mycobacterium species in HIV-infected patients and to evaluate the diagnostic value of different types of body fluids to detect the presence of mycobacteria.

Methods

Patients and study design

This study was a multicentric prospective study of the frequency of Mycobacterium infections in persons infected with HIV. The study was conducted in three major AIDS health care programs of Bogota ("Hospital Universitario San Juan de Dios", "Hospital Regional Simon Bolívar" and "Centro Atención Básica Chapinero del Seguro Social"). From October 1999 to March 2000, a total of 289 HIV-seropositive patients were recruited. Most of the participants met the definition of AIDS, or were in clinical stage C (CDC, 1993). The institutional review board at each site approved the study, and each participant gave written informed consent.

Specimen collection and culture media

For all patients blood, urine, stool and sputum samples were collected. In brief, 5 to 8 mL of blood was obtained in previously labeled Vacutainer™ tubes containing 1.7 mL of heparin as anticoagulant. All patients attempts were made to collect two paired blood cultures samples (n = 648), 2 urine cultures (n = 497), 2 stool cultures (n = 374) and 2 sputum samples (n = 101). In one patient a sample of ascitic fluid, and in other case cerebrospinal fluid (CSF) were obtained. Bacteriologic methods were used as previously described [21,22]. Briefly, blood samples were centrifuged 15 min at 2,000 g and leukocytes recovered by standard methods with Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) and then mixed with a lysing solution that contained 0.45% sodium deoxycholate. After manual mixing, tubes were centrifuged at 3,500 g for 30 minutes in a refrigerated centrifuge at 4,000 g and the supernatant was discarded. The pellet was resuspended, and 0.2% bovine albumin was added to yield a final volume of 2.5 mL. One gr of stool samples was placed in 5 ml of albumin Dubos media and mixed in Vortex™ for 2 min, then incubated at room temperature overnight. Afterwards, equal volumes of a solution of 2% NaOH were mixed in Vortex™ for 2 min and incubated at room temperature in continuos mixing for 15 min. Distilled water was added to complete 50 ml and the mixture was centrifuged at 6,000 g for 30 min. One drop of phenol red was added to the pellet and then neutralized with 2 drops of HCl 2 N. The pellet was resuspended in 2 ml of saline solution, mixed and finally 0.2 ml used for culture. Urine samples were mixed in a ratio of 3:1 with a solution of 20% Na3PO4.12H2O. The mixture was incubated at room temperature for 2 h and then centrifuged at 6,000 g for 30 min. The pellet was used for culture after being decontaminated by Ogawa-Kudoh method. Briefly, sterile slabs were placed in a solution of 4% NaOH during 1 or 2 min and then used to culture samples. Sputum was mixed in equal volume with a solution of 4% Na3PO4.12H2O, incubated at room temperature during 2 h and centrifuged at 6,000 g for 30 min. The pellet was decontaminated by the Ogawa-Kudoh method, as described above, and used for culture. The same procedure was used for the ascitic fluid and CSF samples. All samples were placed in 2 tubes with a biphasic medium: a solid phase Ogawa-Kudoh with iron citrate and a liquid phase of Sauton Twen albumin modified medium and 2 tubes with Stonebrink-Giraldo medium. Readings were made after day 6 and at 2, 4, 6, 8, 12 and 16 week. A positive culture was identified following the criteria of the Centers for Prevention and Disease Control (CDC) [22]. Resistance assay was applied at all Mycobacterium tuberculosis isolates using the proportion method for streptomycin (S), isoniazide (H), thioacetazone (Tb), ethambutol (E) and rifampicin (R). All samples were stained and examined for AFB after centrifugation.

Statistical analysis

Statistical significance for comparison of rates was determined by an exact test when sample sizes were insufficient and by an asymptotic test when sizes were sufficient. All tests were two-sided, and a P value of 0.05 was considered significant. Exact 95% confidence intervals (CI) were calculated for rates by assuming the numerator to be a Poisson variable [23] and for rate ratios using a modified binomial model [24]. Adjusted rate ratios for comparisons among groups defined by demographic variables were calculated by using a Mantel-Haenszel type estimator for incidence-rate data with approximate 95% confidence limits based on the tests [23].

Results

Demographic characteristics

In total, 286 patients were studied, 251 (87.8 %) were men, and 35 (12.2%) were women. The men:women ratio was 7:1. The age range was 3 to 78 years with a median of 35 years (Table 1). Ten patients (3%) were from "Hospital San Juan de Dios"; one-hundred thirty nine patients (49%) were from "Hospital Simón Bolívar" and one hundred thirty seven patients (48%) were from the "Instituto de Seguro Social". Fifty-eight patients were hospitalized at the time of enrollment (20%), and two hundred twenty eight patients (80%) were enrolled at an outpatient clinic. One hundred ninety five patients (68.5%) were in treatment with antiretroviral medication. Sexual preferences were informed in 269 (94%) patients as follows: in males, ninety (33.4%) were homosexual, eighty-six (31.9%) were bisexual and sixty-one (22.7%) were heterosexual. Of the women, twenty-nine (90.6%) were heterosexual and three (9.4%) were bisexual. CDC staging in these patients is shown in Table 1. Viral load was obtained in 180 patients and results varied in a range between less than 50 and 13 millions copies/mL. The median of viral load was 23,420 copies/mL.
Table 1

Demographic characteristics of patients

Distribution by centern%
Hospital San Juan de Dios10
Male990
Women110
Hospital Simon Bolívar139
Male12895
Women2115
Seguro Social137
Male12490
Women1310
Age groups
0 – 1510.35
16 – 253813.3
26 – 4521173.8
46 – 653512.2
66 – 7810.35
1993 CDC stages
A3111
B6924
C18665
Demographic characteristics of patients The symptoms most frequently complaint of at the time of initial enrollment were headaches (48%), loss of weight (43%), and mental status changes (38%). The frequency of each symptom is showed in Figure 1. 29% patients complaint of respiratory symptoms. 13% patients had a history of diagnosis of tuberculosis, and 12% gave a history of previous treatment with antituberculous drugs.
Figure 1

Frequency of clinical symptoms

Frequency of clinical symptoms

Mycobacterium infection

Overall, sixteen of 286 patients (5.6%) were positive for any Mycobacterium species by acid fast staining or culture of any of their samples. In these sixteen cases, fifteen (94%) were positive by culture, and one patient was detected only by acid fast bacilli staining (6%). Fourteen patients (87.5%) were men and two (12.5%) were women. M. tuberculosis was identified in four cases (1.4%). M. avium was isolated in thirteen patients (4.2%). Two patients presented simultaneous infection by M. tuberculosis and M. avium. Tuberculosis was diagnosed in its pulmonary form in two cases, and in another two patients as extrapulmonary. In the patients with pulmonary tuberculosis, the AFB smear of the sputum was positive in one case, and in another case the AFB smear was positive in his stool sample. Culture of stool samples was positive in both cases of pulmonary and in one case of extrapulmonary tuberculosis. M. tuberculosis was detected in different samples of body fluids as well: in sputum, urine, stool samples, and in ascitic fluid (Table 2). All isolates of M. tuberculosis were sensitive to the drugs assayed: streptomycin (S), isoniazide (H), thioacetazone (Th), ethambutol (E) and rifampicin (R).
Table 2

Staining and culture of M. tuberculosis

PatientClinical formType of SampleNumber of SamplesAFB SMEAR POSITIVECULTURE POSITIVE
1DisseminatedSputum222
Urine202
Ascitic fluid111
2*PulmonarySputum222
Stool222
3PulmonarySputum202
Stool212
4GastrointestinalStool222
TOTAL151015

2* This patient also presented positive culture for M. avium

Staining and culture of M. tuberculosis 2* This patient also presented positive culture for M. avium The only species identified as non-tuberculous mycobacteria was M. avium which was detected in 13 patients (4.2%). Two patients had coinfection by M. tuberculosis and M. avium in their sputum culture. One patient was positive only for acid fast bacilli staining in two stool samples but no growth was observed in culture tubes after 16 weeks of incubation. Interestingly, in three patients the direct AFB staining in blood was positive, and M. avium was later identified in these blood cultures (Table 3). M. avium was also detected in other clinical samples: urine, stool and sputum (Table 4).
Table 3

Staining and culture of M. avium in blood samples

AFB smearCulture
PatientSampleNumber of SamplesPositiveNegativePositiveNegative
1blood21120
2blood21120
3blood21120
3*blood20220
urine21120
stool22020
TOTAL1266120

3 Sample after one month of follow. This patient had past history of tuberculosis

Table 4

Staining and culture of M. avium in clinical samples other than blood

AFB SmearCulture
PATIENTSAMPLENumber of SamplesPOSNEGPOSNEG

1Stool20211
2Stool20211
3Stool22020
4Urine20220
5Urine20220
6Urine20211
7Urine20220
8*Sputum22020
9*Sputum22010
TOTAL18612143

8* Patient with past history of TB 9* Patient with simultaneous finding of M. tuberculosis

Staining and culture of M. avium in blood samples 3 Sample after one month of follow. This patient had past history of tuberculosis Staining and culture of M. avium in clinical samples other than blood 8* Patient with past history of TB 9* Patient with simultaneous finding of M. tuberculosis The percent of positive AFB smears and cultures was greater in samples of sputum followed by the samples of stool (Table 5). Samples of urine and stool were valuable to identify most of patients with a M. avium infection, only three patients infected by M. avium were identified solely by blood cultures (Table 6 and 7).
Table 5

Positivity for Mycobacterium infection and type of sample (n = 1622)

SAMPLECULTUREAFB Smear

POSITIVENEGATIVEPOSITIVENEGATIVE
N%n%n%n%
Blood81.264098.830.564599.5
Stool123.236296.811336397
Sputum889392669394
CSF001100001100
Ascitic fluid110000110000
TOTAL402.5158297.5221.3160098.7
Table 6

Clinical findings associated with Mycobacterium avium infection

Clinical findingsOdds RiskCI 95%p
Death*9.7(2.8 – 32)0.0005
Loss of weight*8.0(1.6 – 54)0.004
Diarrhea*4.5(1.1 – 14)0.017
Hemoptysis3.6(0 – 16)0.1
Cough2.1(0.6 – 6.9)0.2
Hospitalization2.5(0.7 – 8.3)0.1
History of past TB2.1(0.4 – 7.9)0.2
Dyspnea1.9(0.5 – 6.8)0.2
Fever1.7(0.5 – 5.5)0.3
Lymphadenopaties1.0(0.2 – 5.7)1.0

* Statistically significant associations p < 0.05

Table 7

Demographic and clinical characteristics in patients with and without Mycobacterium avium infection

Patients with M. avium infection1st and 3rd quartilePatients without M. avium infection1st and 3rd quartilep


N (patients with data)Median or percentN (patients with data)Median or percent
Age1333[23–39]27335[29–40]0.2
Sex male1392%27388%0.5
CD4 cell counts13115[30–223]219164[60–325]0.2
Viral load852,000[5,967–227,941]17223,000[746–147,131]0.5
Use of antiretrovirals1361.5%27268.7%0.8
Time with antiretroviral treatment (months)1029[18–60]17522[12–32]0.2
Time with diagnosis of VIH infection (months)1018.5[15–28]17527[13–50]0.2
Positivity for Mycobacterium infection and type of sample (n = 1622) Clinical findings associated with Mycobacterium avium infection * Statistically significant associations p < 0.05 Demographic and clinical characteristics in patients with and without Mycobacterium avium infection

Association between Mycobacterium avium infection and clinical data

The following factors (Table 6) were significantly associated with a culture positive for M. avium infections: death during time of follow up (odds ratio [OR], 9.7 [95% CI, 2.8–32]), loss of weight (OR, 8 [95% CI, 1.6–54]), and diarrhea (OR, 3.9 [95% CI, 1.1–14]). The mean time of survival during the study was significantly reduced in-patients infected with Mycobacterium avium compared to the ones not infected (154 ± 44 versus 170 ± 37 days, p = 0.01). There were no statistically significant differences in age, sex, clinical stage, CD4 cell count, viral load, use of antiretrovirals drugs or time of diagnosis since HIV infection between patients with or without mycobacterial infection (Table 7). However, there were no patients with M. avium infections in clinical stage A or with a CD4 cell count higher than 500 cells/mm3 (Tables 8 and 9).
Table 8

Clinical stage of HIV infection and positivity for Mycobacterium infection

CLINICAL STAGEPOSITIVETOTAL
A0 (0%)0/31 (0%)
B3 (19%)3/69 (4.4%)
C13 (81%)13/186 (7%)
TOTAL16 (100%)16/286 (5.6%)
Table 9

Relation between CD4 cell count and infection with Mycobacterium

CD4+ cellsPOSITIVESTOTAL
(> 500/mm3)0 (0%)0/24 (0%)
(200–499/mm3)6 (37%)6/83 (7.2%)
(< 200/mm3)8 (50%)8/126 (6.3%)
ND2 (13%)2/53 (3.7%)
TOTAL16 (100%)16/262 (6.1%)
Clinical stage of HIV infection and positivity for Mycobacterium infection Relation between CD4 cell count and infection with Mycobacterium

Discussion

Our study was a prospective study in HIV infected patients in whom an indiscriminate search Mycobacterium infection was done. Clinical suspicion of tuberculosis existed previous to enrollment only in the two patients with pulmonary Mycobacterium tuberculosis infection but not in the other two patients with extrapulmonary tuberculosis. Most of Mycobacterium species isolated were M. avium The frequency that we found was lower than that of previously reported studies for Mycobacterium in HIV infected patients in Colombia. A previous study at the "Hospital San Juan de Dios" in 1996 performed in 92 HIV infected patients found a prevalence of 8% for M. tuberculosis infection [25]. In another study in 101 patients in Cali, Colombia, the prevalence was only 2% [26]. In the present study it was 1.4%. The prevalence of non-tuberculous Mycobacterium species in Cali was 5% [27], and in the current study it was 4%. The lower prevalence of M. tuberculosis, can be related to the introduction of highly active antiretroviral therapy (HAART) that was practically absent in the previous study in Bogota in 1996 but that was being used to treat 68% of the patients in the current study. Our results are also different to the ones reported in a General Hospital, AIDS reference center, in Rio de Janeiro, Brazil [28] where mycobacteria were recovered from 20.6% (313 of 1,517) of all patients, and M. tuberculosis was identified in 94.2% (295/313), and non-tuberculous mycobacteria in 5.8% (18/313). Our results suggest that when antiretroviral therapy is introduced the relative frequency of M. tuberculosis infections is reduced and the one of M. avium infections increases [28]. We found that Mycobacterium avium infection was related to symptomatic diarrhea and greater mortality as has been reported previously [29]. Our study shows that frequency of isolation of M. avium was greater in urine and stool samples. This emphasizes the need to take multiple body fluid samples in order to enhance the opportunity of isolation increasing the microbiologic diagnostic sensitivity. Interestingly, we found that blood AFB smears can be useful to rapidly confirm a clinical diagnosis of disseminated Mycobacterium avium infection. In the present study there were no resistant strains of M. tuberculosis found. In a previous survey in Colombia it was found that M. tuberculosis isolates among new cases in patients without HIV infection showed resistance in 9.5% (4 of 42) [30].

Conclusions

Our study found that 5% of HIV infected patients in Bogota were infected with Mycobacteria and that M. Avium was the predominant species. It becomes evident the need to improve the preventive measures and prompt treatment of this type of opportunistic infection in the HIV infected individuals.

Competing interests

None declared

Pre-publication history

The pre-publication history for this paper can be accessed here:
  22 in total

Review 1.  Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.

Authors:  C R Horsburgh
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

2.  Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1991-08-30       Impact factor: 17.586

3.  Predictive value of the acid fast smear for detection of Mycobacterium tuberculosis in respiratory specimens in a reference center of HIV/AIDS in Rio de Janeiro, Brazil.

Authors:  M B Conde; C M Figueira; R Moraes; L S Fonseca; K Deriemer; A L Kritski
Journal:  Mem Inst Oswaldo Cruz       Date:  1999 Nov-Dec       Impact factor: 2.743

4.  High risk of active tuberculosis in HIV-infected drug users with cutaneous anergy.

Authors:  P A Selwyn; B M Sckell; P Alcabes; G H Friedland; R S Klein; E E Schoenbaum
Journal:  JAMA       Date:  1992 Jul 22-29       Impact factor: 56.272

5.  Restriction fragment length polymorphism (RFLP) analysis and tuberculosis epidemiology.

Authors:  J E Gómez Marín; L Rigouts; L E Villegas Londoño; F Portaels
Journal:  Bull Pan Am Health Organ       Date:  1995-09

6.  Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients.

Authors:  S D Nightingale; L T Byrd; P M Southern; J D Jockusch; S X Cal; B A Wynne
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

7.  An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.

Authors:  C L Daley; P M Small; G F Schecter; G K Schoolnik; R A McAdam; W R Jacobs; P C Hopewell
Journal:  N Engl J Med       Date:  1992-01-23       Impact factor: 91.245

8.  Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy.

Authors:  C R Horsburgh; J A Havlik; D A Ellis; E Kennedy; S A Fann; R E Dubois; S E Thompson
Journal:  Am Rev Respir Dis       Date:  1991-09

9.  Transmission of multidrug-resistant tuberculosis from an HIV-positive client in a residential substance-abuse treatment facility--Michigan.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1991-03-01       Impact factor: 17.586

10.  An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome.

Authors:  B R Edlin; J I Tokars; M H Grieco; J T Crawford; J Williams; E M Sordillo; K R Ong; J O Kilburn; S W Dooley; K G Castro
Journal:  N Engl J Med       Date:  1992-06-04       Impact factor: 91.245

View more
  11 in total

Review 1.  Management of nontuberculous mycobacterial infection in the elderly.

Authors:  Mehdi Mirsaeidi; Maham Farshidpour; Golnaz Ebrahimi; Stefano Aliberti; Joseph O Falkinham
Journal:  Eur J Intern Med       Date:  2014-03-29       Impact factor: 4.487

2.  Virulence and immune response induced by Mycobacterium avium complex strains in a model of progressive pulmonary tuberculosis and subcutaneous infection in BALB/c mice.

Authors:  Mónica González-Pérez; Leonardo Mariño-Ramírez; Carlos Alberto Parra-López; Martha Isabel Murcia; Brenda Marquina; Dulce Mata-Espinoza; Yadira Rodriguez-Míguez; Guillermina J Baay-Guzman; Sara Huerta-Yepez; Rogelio Hernandez-Pando
Journal:  Infect Immun       Date:  2013-08-19       Impact factor: 3.441

3.  The utility of stool cultures for diagnosing tuberculosis in people living with the human immunodeficiency virus.

Authors:  G E Oramasionwu; C M Heilig; N Udomsantisuk; M E Kimerling; B Eng; H D Nguyen; S Thai; C Keo; K D McCarthy; J K Varma; K P Cain
Journal:  Int J Tuberc Lung Dis       Date:  2013-08       Impact factor: 2.373

4.  First insights into the genetic diversity of Mycobacterium tuberculosis isolates from HIV-infected Mexican patients and mutations causing multidrug resistance.

Authors:  Rocio Lopez-Alvarez; Claudia Badillo-Lopez; Jorge F Cerna-Cortes; Ivan Castillo-Ramirez; Sandra Rivera-Gutierrez; Addy C Helguera-Repetto; Diana Aguilar; Rogelio Hernandez-Pando; Sofia Samper; Jorge A Gonzalez-y-Merchand
Journal:  BMC Microbiol       Date:  2010-03-17       Impact factor: 3.605

5.  Mycobacteria causing human cervical lymphadenitis in pastoral communities in the Karamoja region of Uganda.

Authors:  J Oloya; J Opuda-Asibo; R Kazwala; A B Demelash; E Skjerve; A Lund; T B Johansen; B Djonne
Journal:  Epidemiol Infect       Date:  2007-06-29       Impact factor: 2.451

6.  Effect of vitamin A and vitamin C supplementation on oxidative stress in HIV and HIV-TB co-infection at Lagos University Teaching Hospital (LUTH) Nigeria.

Authors:  Oluwamayowa Makinde; Kunle Rotimi; Victor Ikumawoyi; Titilope Adeyemo; Sunday Olayemi
Journal:  Afr Health Sci       Date:  2017-06       Impact factor: 0.927

Review 7.  Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis.

Authors:  Katharina Kranzer; Rein Mgj Houben; Judith R Glynn; Linda-Gail Bekker; Robin Wood; Stephen D Lawn
Journal:  Lancet Infect Dis       Date:  2010-02       Impact factor: 25.071

8.  Routinely detected indicators in plasma have a predictive effect on the identification of HIV-infected patients with non-tuberculous mycobacterial and tuberculous infections.

Authors:  Ren-Tian Cai; Feng-Xue Yu; Zhen Tao; Xue-Qin Qian; Jun Chen; Hong-Zhou Lu
Journal:  Infect Dis Poverty       Date:  2017-11-02       Impact factor: 4.520

9.  Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania.

Authors:  Mecky Matee; Lillian Mtei; Tarja Lounasvaara; Wendy Wieland-Alter; Richard Waddell; Johnson Lyimo; Muhammad Bakari; Kisali Pallangyo; C Fordham von Reyn
Journal:  BMC Public Health       Date:  2008-02-21       Impact factor: 3.295

10.  Prevalence and predictors of tuberculosis coinfection among HIV-seropositive patients attending the Aminu Kano Teaching Hospital, northern Nigeria.

Authors:  Zubairu Iliyasu; Musa Babashani
Journal:  J Epidemiol       Date:  2009-03-06       Impact factor: 3.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.